Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EI-201 intravenous mRNA immunotherapy in recurrent or metastatic HPV16-positive cancers
NL-OMON56720Phase 1Not yet recruiting
- Sponsor
- eTheRNA immunotherapies
- Start
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of EI-201 and pembrolizumab in oropharyngeal cancer, Cervical Cancer (CC), Vulval carcinoma and 3 more (2 cohorts), sponsored by eTheRNA immunotherapies. Primary endpoints: Dose-limiting toxicity, maximum tolerated dose, recommended phase 2 dose, serious adverse events, and adverse events and Objective response rate. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
EI-201pembrolizumab
03
Conditions
oropharyngeal cancerCervical Cancer (CC)Vulval carcinomavaginal canceranal cancer
Beyond the preview
Go deeper on NL-OMON56720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56720.